BMRA
BIOMERICA INCPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- B Aug 20 to Aug 26 2 days of insider buys: $158.0K by 5 insiders, avg $1.60
- E Aug 27 Offering: Biomerica Announces $2.23 Million Financing
- R Aug 27 Biomerica insiders, including the CEO and Executive Vice Chairman, m…
- X Aug 31 Short interest jumps 215.6% to 57.9K
- R Sep 1 Biomerica reported fiscal 2026 Q4 net sales of ~$875K (+17% YoY) and…
- X Sep 15 Short interest falls 35.8% to 37.2K
- R Sep 25 Biomerica filed a $250M universal shelf registration statement (S-3)…
- X Sep 30 Short interest falls 25.6% to 27.7K
Signal stack
Where each data set points today.
- InsidersBULLISH
5 insiders bought $158.0K at an average $1.60. No open-market sales. Price is 8% above their cost.
- InstitutionsMIXED
Q2 2026: 1 added (0 new), 1 trimmed or exited.
- TrendDOWNTREND
16% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $42.9K |
| UBS Group AG | DOUBLED | $12.2K |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | $118.3K |
| UBS Group AG | NEAR_EXIT | $1.1K |
| UBS Group AG | DOUBLED | $14.6K |
| CITIGROUP INC | DOUBLED | $6.1K |
| UBS Group AG | NEAR_EXIT | $325.00 |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $88.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Oct 2020| Date | Firm | Rating |
|---|---|---|
| Oct 19, 2020 | Aegis Capital MAINTAIN | Buy |
| Sep 4, 2020 | Aegis Capital MAINTAIN | Buy |
| Aug 21, 2020 | Aegis Capital INITIATE | Buy |
| Dec 17, 2018 | B. Riley Securities MAINTAIN | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Aug 26, 2026 | Irani Zackary S. Chief Executive Officer | BUY | $50.0K |
| Aug 26, 2026 | BARBIERI ALLEN Executive Vice Chairman | BUY | $32.0K |
| Aug 26, 2026 | MOATAZEDI DAVID Director | BUY | $16.0K |
| Aug 26, 2026 | Chin Eric Director | BUY | $10.0K |
| Aug 20, 2026 | Gary M. Huff Director | BUY | $50.0K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
11 filings · 2 press releases · 0 bullish · 3 bearish · 3 mixed · 5 neutral- NEUTRAL DEF 14AOct 16, 2026
Biomerica's 2026 definitive proxy statement schedules its annual meeting for December 11, 2026…
Monitor the December 11 annual meeting for say-on-pay vote outcome and stockholder sentiment on the equity plan increase. The outstanding $500,000 related-party note to CEO Irani for the Diagnosis…
- NEUTRAL 8-KOct 15, 2026
Board member David Moatazedi will not stand for re-election at Biomerica's 2026 Annual Meeting on…
Monitor the 2026 Annual Meeting proxy statement for the Board's nominee to replace Moatazedi and any changes to committee composition. No immediate trading signal.
- NEUTRAL EFFECTOct 8, 2026
Biomerica's S-3 shelf registration (File No. 333-299133) became effective on October 7, 2026…
Monitor for any prospectus supplement indicating actual takedowns or pricing, which would signal near-term selling pressure. The shelf's effectiveness alone is routine but creates a persistent…
- NEUTRAL EFFECTOct 8, 2026
The SEC declared effective Biomerica's S-3 shelf registration (File No. 333-299120) on October 7…
Monitor for any prospectus supplement announcing a takedown under the shelf, which would crystallize dilution. The resale of 1.4M shares by selling stockholders could create near-term overhang.
All BMRA filing & press-release reports (13)
- DEF 14A reportOct 16, 2026
- 8-K reportOct 15, 2026
- EFFECT reportOct 8, 2026
- EFFECT reportOct 8, 2026
- S-3 reportSep 25, 2026
- S-3 reportSep 24, 2026
- PRESS-RELEASE reportSep 1, 2026
- CLUSTER reportAug 27, 2026
- 8-K reportAug 26, 2026
- 8-K reportJun 4, 2026
- PRESS-RELEASE reportMay 28, 2026
- PRESS-RELEASE reportApr 14, 2026
- PRESS-RELEASE reportApr 13, 2026